NYU Langone Medical Center

NYU Langone Transplant Institute Celebrates Milestone Lung Transplant Procedure

Retrieved on: 
Monday, January 11, 2021

NEW YORK, Jan. 11, 2021 /PRNewswire/ --Last month the NYU Langone Transplant Institute achieved a milestone lung transplant procedure: its first for a patient whose lungs were irretrievably damaged by COVID-19, and its 100th lung transplant since the program launched in January 2018.

Key Points: 
  • NEW YORK, Jan. 11, 2021 /PRNewswire/ --Last month the NYU Langone Transplant Institute achieved a milestone lung transplant procedure: its first for a patient whose lungs were irretrievably damaged by COVID-19, and its 100th lung transplant since the program launched in January 2018.
  • Since 2017, NYU Langone has launched five new solid organ transplant programs: heart, lung, pancreas, pediatric kidney, and pediatric heart.
  • Alongside the lung transplant program's notable achievements, NYU Langone's adult heart transplant program also ranks top in the nation according to recently published data from the Scientific Registry of Transplant Recipients.
  • "I'm extremely proud to see the Lung Transplant program achieve such incredible success less than three years after its launch," says Robert Montgomery, MD , DPhil, Director of the NYU Langone Transplant Institute and chair of the Department of Surgery.

NYU Langone Health Brings World-Class Orthopedic Care To Staten Island

Retrieved on: 
Wednesday, January 6, 2021

Expanding its orthopedic care team, NYU Langone has welcomed foot and ankle surgeon Raymond Walls, MD , from Yale School of Medicine, to treat patients at NYU Langone Orthopedic AssociatesStaten Island alongside surgeons Vinay Agarwal, MD , Jadi E. De Tolla, MD , Tina Raman, MD , and Spencer Stein, MD .

Key Points: 
  • Expanding its orthopedic care team, NYU Langone has welcomed foot and ankle surgeon Raymond Walls, MD , from Yale School of Medicine, to treat patients at NYU Langone Orthopedic AssociatesStaten Island alongside surgeons Vinay Agarwal, MD , Jadi E. De Tolla, MD , Tina Raman, MD , and Spencer Stein, MD .
  • Surgical procedures, if necessary, are performed nearby at NYU Langone HospitalBrooklyn , or at the world-renowned NYU Langone Orthopedic Hospital and the Joan H. and Preston Robert Tisch Center at Essex Crossing outpatient surgery center in Manhattan.
  • To minimize travel between boroughs, pre- and postsurgical appointments are scheduled at NYU Langone Orthopedic AssociatesStaten Island.
  • Thompson Professor of Orthopedic Surgery and chair of the Department of Orthopedic Surgery at NYU Langone.

SiriusXM and NYU Langone Health Provide Free Access to Doctor Radio Channel, Offering Covid-19 Updates and Expert Advice

Retrieved on: 
Friday, December 11, 2020

The free access and new programming on Doctor Radio coincides with the Food and Drug Administration's (FDA)expected approvalof a Covid-19 vaccine under Emergency Use Authorization.

Key Points: 
  • The free access and new programming on Doctor Radio coincides with the Food and Drug Administration's (FDA)expected approvalof a Covid-19 vaccine under Emergency Use Authorization.
  • Since the beginning of the pandemic, SiriusXM in conjunction with NYU Langone Health, has dedicated the Doctor Radio channel to providing the public with the latest information on the coronavirus outbreak, while continuing to address everyday health concerns.
  • The department chairs at NYU Langone will focus on the positive medical headlines that we may have missed over the past year.
  • In March, Doctor Radio premiered a biweekly two-hour show, "Doctor Radio Reports," focused on all aspects of the Covid-19 pandemic.

NYU Langone Gastroenterology Appoints Director of Pancreatic Disease Program

Retrieved on: 
Thursday, December 3, 2020

NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Tamas A. Gonda, MD , a nationally renowned advanced endoscopist and translational researcher in pancreatic disease, has joined NYU Langone Health as the director of the Pancreatic Disease Program within the Division of Gastroenterology and Hepatology.

Key Points: 
  • NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Tamas A. Gonda, MD , a nationally renowned advanced endoscopist and translational researcher in pancreatic disease, has joined NYU Langone Health as the director of the Pancreatic Disease Program within the Division of Gastroenterology and Hepatology.
  • Prior to joining NYU Langone, Dr. Gonda served on the faculty at Columbia University College of Physicians & Surgeons, where he was medical director of the Pancreatic Cyst Surveillance Program, director of Endoscopic Research, and director of Gastroenterology Services at the institution's Pancreatic Center.
  • Dr. Gonda will establish a comprehensive Pancreatic Disease Program within the Division of Gastroenterology & Hepatology at NYU Langone, serving both inpatients and outpatients who are facing diagnoses across the range of pancreatic disease, including acute pancreatitis, chronic pancreatitis, pancreatic insufficiency, pancreatic cysts, pre-cancerous and high-risk pancreatic conditions, and pancreatic cancer.
  • The program will integrate gastroenterology, advanced endoscopy, surgery, and all needed services, and will feature a strong research mission.

NYU Langone Health Expands Comprehensive Lung Cancer Care in Brooklyn

Retrieved on: 
Monday, November 16, 2020

NYU Langone Health's Perlmutter Cancer Center , a National Cancer Institutedesignated Comprehensive Cancer Center, in partnership with NYU Langone HospitalBrooklyn is growing its state-of-the-art lung cancer care in New York City's largest borough with a new expansion of treatment and screening services.

Key Points: 
  • NYU Langone Health's Perlmutter Cancer Center , a National Cancer Institutedesignated Comprehensive Cancer Center, in partnership with NYU Langone HospitalBrooklyn is growing its state-of-the-art lung cancer care in New York City's largest borough with a new expansion of treatment and screening services.
  • Abraham Chachoua, MD , the Jay and Isabel Fine Professor of Oncology at NYU Grossman School of Medicine, and associate director for cancer services and clinical director of solid tumor oncology at Perlmutter Cancer Center, was recently named the new director of Perlmutter Cancer Center's Lung Cancer Center , underscoring NYU Langone's commitment to strengthening its lung cancer services in Brooklyn and across the Perlmutter Cancer Center network.
  • "When we built the state-of-the-art Perlmutter Cancer CenterSunset Park last year, it was our intent to enhance and complement the excellent oncologic care already provided by our physicians in Brooklyn," says Dr. Chachoua.
  • After piloting an innovative approach to lung cancer screening at the Sunset Park Family Health Center at NYU LangoneSecond Avenue , the screening program will expand other health center locations and practices across Brooklyn.

NYU Langone Health to Enroll Healthy Volunteers In Clinical Trial for COVID-19 Vaccine

Retrieved on: 
Wednesday, November 11, 2020

NYU Langone Health was chosen as a trial center thanks in part to the expertise of Mulligan, a leader in infectious disease research programs that have over decades yielded vaccine candidates for HIV and other viruses.

Key Points: 
  • NYU Langone Health was chosen as a trial center thanks in part to the expertise of Mulligan, a leader in infectious disease research programs that have over decades yielded vaccine candidates for HIV and other viruses.
  • Five research clinics within NYU Langone Health will vaccinate study participants, with the Vaccine Center at NYU Langone's Tisch Hospital in Manhattan coordinating the effort.
  • Other system hospitals that will serve as vaccinating sites include NYU Langone HospitalBrooklyn and NYU Langone HospitalLong Island (formerly known as NYU Winthrop Hospital).
  • NYU Langone Health is one of only 10 specialized NIH-funded Vaccine and Treatment Evaluation Units, or VTEUs, in the nation, several of which are participating in the AstraZeneca COVID-19 vaccine trial.

NYU Grossman School of Medicine's Institute of Graduate Biomedical Sciences Named for World Renowned Scientist and Philanthropist Jan T. Vilcek, MD, PhD

Retrieved on: 
Tuesday, November 3, 2020

The newly-named Vilcek Institute of Graduate Biomedical Sciences will continue its long tradition to prepare graduate students for careers in biomedical research.

Key Points: 
  • The newly-named Vilcek Institute of Graduate Biomedical Sciences will continue its long tradition to prepare graduate students for careers in biomedical research.
  • The physicians, researchers, students, and patients across NYU Grossman School of Medicine and NYU Langone Health continue to benefit greatly from his scientific achievements."
  • The Vilcek Institute of Graduate Biomedical Sciences trains PhD and MD/PhD candidates to study some of today's most urgent biomedical problems under the mentorship of renowned faculty members.
  • "Naming our graduate school after Dr. Vilcek reflects our steadfast support for students who come here from across the globe to conduct groundbreaking research," said Naoko Tanese, PhD, Associate Dean for Biomedical Sciences and Director, Vilcek Institute of Graduate Biomedical Sciences.

Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management

Retrieved on: 
Tuesday, November 3, 2020

FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Companys Pure-Vu GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.

Key Points: 
  • FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Companys Pure-Vu GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.
  • Seth Gross, MD, Director of Clinical Care and Quality in the Division of Gastroenterology at NYU Langone Health, has worked closely with Motus GI on the development of this protocol at NYU Langone Health, and will work with Motus GI to provide training and support for use of the Pure-Vu System.
  • Suboptimal bowel preparation can lead to missed diagnosis and extend exam time for inpatient GI procedures, Dr.
  • Within the last year, the Company initiated its commercial launch of the Pure-Vu System in the U.S. with an initial focus on inpatient colonoscopy.

OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY

Retrieved on: 
Thursday, October 29, 2020

OHSU is based in Portland, Oregon, and is set to begin enrolling patients under the leadership of Martin A. Schreiber, M.D.

Key Points: 
  • OHSU is based in Portland, Oregon, and is set to begin enrolling patients under the leadership of Martin A. Schreiber, M.D.
  • "We are thrilled to have OHSU, one of the leading academic and research centers in the United States, join NYU Langone Health in this critical multicenter COVID-19 BVA trial," said Michael Feldschuh, CEO and President of Daxor.
  • We believe our test can have a significant impact on patient triage, outcomes and optimal use of resources.
  • This study aims to show the implications of COVID as an endothelial disease utilizing this unique measure.

CivaTech Oncology and NYU Langone Health Launch NIH-sponsored Trial to Fight Lung Cancer

Retrieved on: 
Tuesday, October 27, 2020

Physicians from NYU Langone Health and its Perlmutter Cancer Center successfully treated their first patient in an NIH/NCI- sponsored clinical trial using CivaSheet ,to improve lung cancer patients outcomes.

Key Points: 
  • Physicians from NYU Langone Health and its Perlmutter Cancer Center successfully treated their first patient in an NIH/NCI- sponsored clinical trial using CivaSheet ,to improve lung cancer patients outcomes.
  • CivaSheets integrated shielding protects healthy surrounding organs, enabling a higher dose than can be administered using other treatment options.
  • Approximately 234,000 patients in the U.S. are diagnosed with lung cancer each year, and of those, 30- 55% with non-small cell lung cancer develop recurrence.
  • NYU Langone Health is participating in this clinical trial with several other nationally recognized cancer centers in the U.S.
    For more information on clinics participating in the lung cancer trial; https://www.clinicaltrials.gov/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005681/en/